Molecular Mechanism and Progression of Primary Resistance to EGFR-TKI
- Analysis of 2 Cases / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 52-56, 2019.
Article
in Chinese
| WPRIM
| ID: wpr-772331
ABSTRACT
Tyrosine kinase inhibitor (TKI) have been proved to be effective in the treatment of advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) sensitive mutation, which is superior to chemotherapy. However, there are still some patients with sensitive mutations have primary drug resistance. It may be related to the coexistence of susceptible and resistant mutations of EGFR gene, downstream mutations of EGFR pathway, MET amplification and BIM deletion polymorphism. We present 2 cases of primary drug resistance and analyze the reasons.
.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Diagnostic Imaging
/
Treatment Outcome
/
Fatal Outcome
/
Carcinoma, Non-Small-Cell Lung
/
Disease Progression
/
Drug Resistance, Neoplasm
/
Therapeutic Uses
/
Protein Kinase Inhibitors
/
Drug Therapy
/
ErbB Receptors
Type of study:
Diagnostic study
Limits:
Humans
/
Male
Language:
Chinese
Journal:
Chinese Journal of Lung Cancer
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS